Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: galanis e. Gynecol Oncol. 2023 Feb;169:173. doi: 10.1016/j.ygyno.2022.11.010. Epub 2022 Nov 28. Gynecol Oncol. 2023. PMID: 36456375 No abstract available.
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rocconi RP, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: galanis e. Gynecol Oncol. 2021 Jun;161(3):676-680. doi: 10.1016/j.ygyno.2021.03.009. Epub 2021 Mar 11. Gynecol Oncol. 2021. PMID: 33715892 Clinical Trial.
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Rocconi RP, Stevens EE, Bottsford-Miller JN, Ghamande SA, Elder J, DeMars LL, Munkarah A, Aaron P, Stanbery L, Wallraven G, Bognar E, Manley M, Horvath S, Manning L, Walter A, Galanis E, Herzog T, Monk BJ, Coleman RL, Nemunaitis J. Rocconi RP, et al. Among authors: galanis e. Cancer Gene Ther. 2022 Mar;29(3-4):369-382. doi: 10.1038/s41417-021-00317-5. Epub 2021 Mar 22. Cancer Gene Ther. 2022. PMID: 33753870 Clinical Trial.
Aurora-A Kinase as a Promising Therapeutic Target in Cancer.
D'Assoro AB, Haddad T, Galanis E. D'Assoro AB, et al. Among authors: galanis e. Front Oncol. 2016 Jan 6;5:295. doi: 10.3389/fonc.2015.00295. eCollection 2015. Front Oncol. 2016. PMID: 26779440 Free PMC article. Review.
Extraskeletal Osteosarcoma: Outcomes and the Role of Chemotherapy.
Paludo J, Fritchie K, Haddox CL, Rose PS, Arndt CAS, Marks RS, Galanis E, Okuno SH, Robinson SI. Paludo J, et al. Among authors: galanis e. Am J Clin Oncol. 2018 Sep;41(9):832-837. doi: 10.1097/COC.0000000000000397. Am J Clin Oncol. 2018. PMID: 28622153 Free PMC article.
Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.
Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF. Sarkaria JN, et al. Among authors: galanis e. Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175. Neuro Oncol. 2018. PMID: 29016900 Free PMC article. Review.
365 results